Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pasithea Therapeutics Corp ( (KTTA) ) has shared an update.
On November 28, 2025, Pasithea Therapeutics Corp announced a public offering of 80,000,000 shares of common stock or pre-funded warrants, raising approximately $60 million in gross proceeds. The offering, which closed on December 1, 2025, was led by healthcare-focused investors and is expected to extend the company’s cash runway through at least the first half of 2028. The net proceeds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions. Company insiders, including executives and board members, participated in the offering, purchasing shares at the same price as other investors.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp is a clinical-stage biotechnology company focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor. This drug is intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently conducting Phase 1 clinical trials for PAS-004 in advanced cancer patients and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Average Trading Volume: 6,759,192
Technical Sentiment Signal: Hold
Current Market Cap: $8.63M
For detailed information about KTTA stock, go to TipRanks’ Stock Analysis page.